Charge-reversal biodegradable MSNs for tumor synergetic chemo/photothermal and visualized therapy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Given the difficulties of biodegradation of mesoporous silica nanoparticles (NPs), enrichment and penetration of tumor sites, and real-time monitoring of the treatment process, we developed a kind of mannose-doping doxorubicin-loading mesoporous silica nanoparticle (MSN-Man-DOX) and coated by polydopamine-Gd3+ (PDAGd) metal-phenolic networks, as well as modified by poly (2-Ethyl-2-Oxazoline) (PEOz), constructing a novel nanomedicine MSN-Man-DOX@PDA-Gd-PEOz. Its pH-responsive charge reversal, photothermal, biodegradation, drug release, and nuclear magnetic resonance imaging properties were evaluated in vitro. Cellular uptake, tumor penetration, lysosomal escape properties, as well as cell safety and toxicity of the nanoplatform were investigated through cell experiments. Finally, the MRI, organ distribution, photothermal condition, and comprehensive anti-tumor therapy in vivo were evaluated comprehensively through animal experiments. Research results showed that MSN-Man-DOX@PDA-Gd-PEOz had outstanding tumor enrichment and penetration abilities, which can produce excellent treatment effects through the synergistic effect of chemotherapy and photothermal therapy (PTT) with the function of magnetic resonance imaging (MRI) contrast agent for disease monitoring. Besides, after finishing the therapeutic effect MSN-Man-DOX@PDA-Gd-PEOz can be biodegraded, so it had a good prospect of clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, Y., Ai, K., & Lu, L. (2014) · Chemical Reviews · doi:10.1021/cr400407a · Cited by 4,794
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160
Zeng, W., Zhang, H., Deng, Y., Jiang, A., Bao, X., Guo, M., Li, Z., Wu, M., Ji, X., Zeng, X., et al. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.124494 · Cited by 256
Self-citation
Cited by
New opportunities and old challenges in the clinical translation of nanotheranostics
Gawne, P. J., Ferreira, M., Papaluca, M., Grimm, J., & Decuzzi, P. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00581-x · Cited by 255
Research progress on nano-sensitizers for enhancing the effects of radiotherapy
Zhang, Y., Han, X., Liu, Y., Wang, S., Han, X., & Cheng, C. (2022) · Materials Advances · doi:10.1039/d2ma00094f · Cited by 44
Liu, Q., Yang, L., Wang, L., Li, Z., Yu, Y., Zheng, Y., Lian, D., Li, X., Chen, H., Mei, L., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125064 · Cited by 28
Self-citationYin, X., Li, Z., Zhang, Y., Zeng, X., Wang, Q., & Liang, Z. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1174014 · Cited by 15
“Nanomedicine platforms can also achieve synergistic anticancer therapy, such as chemotherapy combined with photothermal therapy (Liu et al., 2018; Peng et al., 2018; Li et al., 2021; Li et al., 2022), photodynamic therapy (Tao et al.”
BackgroundSelf-citationSize transformable organic nanotheranostic agents for NIR-II imaging-guided oncotherapy
Su, P., Sun, W., Wang, G., Xu, H., Bao, B., & Wang, L. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.10.038 · Cited by 6
Metadata
- Authors
- Li, Z., Yang, Y., Wei, H., Shan, X., Wang, X., Ou, M., Liu, Q., Gao, N., Chen, H., Mei, L., & Zeng, X.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 338
- Pages
- 719-730
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W3201575333
- Cited by
- 199
- References
- 3
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.